RxSight, Inc. (RXST) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-25

Business type: Asset play

How it makes money

It earns from cataract patients paying out-of-pocket fees to surgeons who use its hardware and lenses to customize vision after surgery.

The company sells a two-part system: a proprietary lens implanted during cataract surgery and a light delivery device used weeks later to adjust the lens's power. Revenue is driven by the volume of lens implants, as patients pay a premium fee—typically $2,000 to $5,000—to access the customization benefits that standard, insurance-covered lenses lack.

What protects it: the moat

Management claims its proprietary silicone-based technology and installed base of devices provide a competitive edge, though its patents face inherent risks.

The company asserts that its photosensitive material and light-adjustment process offer a unique advantage over fixed-power lenses. Protection relies on its ability to maintain these patents and the difficulty for rivals to replicate its specific post-surgical adjustment capabilities.

What growth costs

It must heavily fund sales and marketing infrastructure and maintain supply chains to support the growth of its razor-and-blade model.

Growth requires constant investment in training a specialized sales force and expanding its installed base of light delivery devices. Because it relies on single-source suppliers for critical components, the company must also manage the logistics of manufacturing to ensure it can fulfill ongoing lens volume demand.

What could damage it

Dependency on single-source manufacturing creates a bottleneck where supply chain failure directly halts the ability to sell its primary revenue-generating lenses.

Because the company lacks internal control over the production of critical system components, a disruption at a single-source supplier would prevent it from delivering the lenses that generate the majority of its cash, directly paralyzing the business model.

About RxSight, Inc.

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Other companies in Medical Devices